These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
257 related articles for article (PubMed ID: 20445188)
1. Oral cladribine and fingolimod for relapsing multiple sclerosis. Mann H N Engl J Med; 2010 May; 362(18):1738; author reply 1739-40. PubMed ID: 20445188 [No Abstract] [Full Text] [Related]
2. Oral therapy for multiple sclerosis--sea change or incremental step? Carroll WM N Engl J Med; 2010 Feb; 362(5):456-8. PubMed ID: 20089958 [No Abstract] [Full Text] [Related]
3. [Development of oral therapies for multiple sclerosis--fingolimod, cladribine and other drugs]. Hecht B Med Monatsschr Pharm; 2010 Apr; 33(4):120-30; quiz 131-2. PubMed ID: 20429402 [TBL] [Abstract][Full Text] [Related]
4. Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration. Massberg S; von Andrian UH N Engl J Med; 2006 Sep; 355(11):1088-91. PubMed ID: 16971715 [No Abstract] [Full Text] [Related]
17. [Dilemma of further therapeutic step in remitting-relapsing multiple sclerosis in case of ineffectiveness of first-line treatment: fingolimod or natalizumab?]. Gábor L Ideggyogy Sz; 2014 Mar; 67(3-4):141. PubMed ID: 26118259 [No Abstract] [Full Text] [Related]
18. Fingolimod for the treatment of relapsing multiple sclerosis. Singer BA Expert Rev Neurother; 2013 Jun; 13(6):589-602. PubMed ID: 23738997 [TBL] [Abstract][Full Text] [Related]
19. Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine. Warnke C; Wiendl H; Hartung HP; Stüve O; Kieseier BC Drug Des Devel Ther; 2010 Jul; 4():117-26. PubMed ID: 20689698 [TBL] [Abstract][Full Text] [Related]